MagForce AG Co-Sponsors Brain Cancer Patient Event of University Hospital Münster held on occasion of the 2017 World Brain Tumor Day

Berlin, Germany and Nevada, USA, June 08, 2017 - MagForce AG (Frankfurt, Scale, XETRA: MF6, ISIN: DE000A0HGQF5), a leading medical device company in the field of nanomedicine focused on oncology, is delighted to announce that the Company is again co-sponsoring an event for brain cancer patients and their relatives held on occasion of the 2017 World Brain Tumor Day. The event will be hosted by the Brain Tumor Center of the University Hospital Münster and will take place on June 10, 2017.


Under this year’s slogan “Wir rocken das! Psychoonkologische Begleitung mit viel Schwung! (We will rock that! Dynamic psycho-oncological support program)!” the event will, through a series of dance and creative workshops, feature engaging exercises aimed at involving all senses. Creative arts therapies are the focal point of the program. Such complimentary therapies have been found to help manage the emotional and psychological side effects that often result from cancer diagnosis and treatment. Furthermore, participants will have the opportunity for one-on-one discussions with experts in the fields of individual coaching, art therapy and psycho-oncology throughout the day. The event will take place at the premises of the University Münster Sports Center in Münster, Germany, on Saturday, June 10, 2017, from 11am to 2.30pm CET. MagForce will be available for questions regarding its NanoTherm® Therapy for the treatment of brain tumors and will be represented by a booth right at the venue.


The University Hospital Münster was the second medical center in Germany to install a NanoActivator® device, following the Charité University Hospital in Berlin. Prof. Dr. med. Walter Stummer, Director of the Neurosurgery Department at the University Hospital Münster and Chair of the UKM Brain Tumor Centre, has initiated the NanoTherm® Therapy for treatment of brain tumors patients beginning of 2015.


For further information regarding program (German only) and registration, please visit: http://klinikum.uni-muenster.de/index.php?id=hirntumorzentrum-aktuell


About the World Brain Tumor Day

This commemoration day was initialised by the Deutsche Hirntumorhilfe e.V. (German Brain Tumor Association) in 2000. Because brain tumors occur rather seldom in comparison to other cancers, they are little-noticed by the public. With the aim of directing public attention to the situation of brain tumor patients and appealing for solidarity with patients and their dependants, the World Brain Tumor Day takes place every year on June 8th. It is also a reminder directed at the responsible persons in the fields of politics and economy to assume their social responsibility. Active support of research and an increased interdisciplinary collaboration are the ways to develop new therapies and improve the chances of healing. Until that, it is essential to campaign together to advance the quality of life of patients, to give hope and show solidarity – it is essential to send a signal.


Role of NanoTherm® Therapy in the Treatment of Brain Tumors

NanoTherm® therapy is an intratumoral thermotherapy which aims to help patients with brain tumors. It can be used as a monotherapy or in combination with radiotherapy and/or chemotherapy to enhance their effectiveness.


With NanoTherm® therapy, the magnetic fluid injected into a tumor is heated through a very fast alternating magnetic field. Through the heat, tumor cells are either destroyed or sensitized for additional therapies such as radiotherapy and/or chemotherapy; thus, the efficacy of the additional therapies is improved.


MagForce AG has CE mark (European Certification) in Germany and in the EU 28 to treat brain tumors with NanoTherm® therapy.


About MagForce AG and MagForce USA, Inc.

MagForce AG, listed in the Scale segment of the Frankfurt Stock Exchange (MF6, ISIN: DE000A0HGQF5), together with its subsidiary MagForce USA, Inc. is a leading medical device company in the field of nanomedicine focused on oncology. The Group's proprietary NanoTherm® therapy enables the targeted treatment of solid tumors through the intratumoral generation of heat via activation of superparamagnetic nanoparticles.


NanoTherm®, NanoPlan®, and NanoActivator® are components of the therapy and have received EU-wide regulatory approval as medical devices for the treatment of brain tumors. MagForce, NanoTherm, NanoPlan, and NanoActivator are trademarks of MagForce AG in selected countries.



For more information, please visit: www.magforce.com.       

Get to know our Technology: video (You Tube)

Stay informed and subscribe to our mailing list.



This release may contain forward-looking statements and information which may be identified by formulations using terms such as "expects", "aims", "anticipates", "intends", "plans", "believes", "seeks", "estimates" or "will". Such forward-looking statements are based on our current expectations and certain assumptions, which may be subject to a variety of risks and uncertainties. The results actually achieved by MagForce AG may substantially differ from these forward-looking statements. MagForce AG assumes no obligation to update these forward-looking statements or to correct them in case of developments, which differ from those, anticipated.



Barbara von Frankenberg
Vice President
Communications & Investor Relations
T +49-30-308380-77
E-Mail: bfrankenberg@magforce.com